Calcipotriol
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Calcipotriol: From Psoriasis (Topical Vitamin D3 Analogue) to Seborrheic Keratosis
One-Sentence Summary
Calcipotriol is a topical vitamin D3 analogue, marketed in Singapore as ointment and gel products (including combination products with a corticosteroid). The TxGNN model predicts it may be effective for seborrheic keratosis, with no registered clinical trials but 4 publications (small clinical studies, case reports and reviews) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records compiled for this report (the approved indication text is empty). Calcipotriol is generally known as a topical psoriasis treatment. |
| Predicted New Indication | Seborrheic keratosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, calcipotriol is a vitamin D3 analogue that binds the vitamin D receptor in keratinocytes. This inhibits keratinocyte proliferation, promotes differentiation and can induce apoptosis.
Seborrheic keratosis is a benign, slow-growing epidermal tumour of thickened (hyperkeratotic) skin, mainly seen in older adults. Its abnormal keratinocyte growth is the same cellular process that calcipotriol modulates in psoriasis. This plausibly explains the reported regression of seborrheic keratosis and senile warts under topical vitamin D3 ointments. The study designs were inferred from titles and abstracts only and need verification.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36752725 | 2023 | Case series (12 patients; design inferred) | Australas J Dermatol | 0.005% calcipotriol ointment for solitary flat seborrheic keratosis on the face. After 3-8 months, lesions regressed completely, with remission lasting 6-10 years. |
| 16043912 | 2005 | Clinical study | J Dermatol | Topical vitamin D3 (tacalcitol, calcipotriol or maxacalcitol) for senile warts in 116 cases over 3-12 months. 35 cases (30.2%) responded, and apoptosis is suggested as the mechanism. |
| 15577148 | 2004 | Clinical report / review | Clinical Calcium | Active topical vitamin D3 applied once or twice daily to senile warts (seborrheic keratosis) as an alternative to surgery, freezing or laser. |
| 10721662 | 2000 | Case report | J Dermatol | Marked response of keratosis lichenoides chronica (a related keratotic skin disease) to calcipotriol ointment. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06587P | DAIVONEX OINTMENT 50 mcg/g | Ointment | Not stated in available records |
| SIN14318P | Daivobet Gel 50mcg/g + 0.5mg/g | Gel | Not stated in available records |
| SIN12241P | DAIVOBET OINTMENT | Ointment | Not stated in available records |
Safety Considerations
- Disease-level cautions (from the TxGNN knowledge graph, not label text): The knowledge graph links calcipotriol to the following conditions as contraindications.
- Calcium and vitamin D-related disorders: hypercalcemia, hypervitaminosis, nephrocalcinosis, calcinosis, calciphylaxis, and other calcium or phosphorus metabolism disorders.
- Adrenal disorders: adrenocortical insufficiency and Addison disease.
- Skin and vascular conditions: skin atrophy, telangiectasis and other capillary diseases, peripheral vascular disease, and several ichthyoses, Darier disease and guttate psoriasis.
- Drug Interactions: The interaction screen returned 84 records, all with unclassified severity level. Examples include corticosteroids (hydrocortisone, prednisone, prednisolone, triamcinolone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, rabeprazole), doxycycline, clarithromycin, metformin and simvastatin. Their clinical significance needs confirmation.
Please refer to the package insert for warnings and contraindications, which were not available for this report.
Conclusion and Next Steps
Decision: Hold (research question)
Rationale: The mechanism is plausible and small clinical studies and case reports report lesion regression, but there are no registered trials and no controlled studies. The study designs were inferred from titles and abstracts, and the package insert safety data could not be obtained. Seborrheic keratosis is also a benign condition that has other established treatments.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Approved indication text for the Singapore licences
- Mechanism of action data from DrugBank
- Verification of study designs and outcomes in the retrieved publications
- A controlled trial (preferably randomised) of topical calcipotriol versus standard treatment for seborrheic keratosis, with attention to local skin irritation and facial use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.